Asia > Health

Health in Asia

  • India’s fifth major drugmaker

    INDIA, 2013/03/17 India’s fifth major drugmaker by sales, Cipla Limited, has made a $512 million cash offer to acquire 100 % ordinary shares of South Africa’s pharmaceutical manufacturer, Cipla Medpro at R10 ($1.13)per share.

  • China published a plan to reduce the world’s major people of smokers

    CHINA, 2012/12/22 China published a plan to reduce the world’s major people of smokers as part of a 2005 treaty, without implementing recommendations such as warning labels that include photos of rotten teeth and diseased lungs. China plans to cut the number of smokers to 25 % of the people by 2015 from 28.1 % in 2010, according to the plan published by the Ministry of Industry and Data Technology yesterday years after the country signed the treaty that recommends the graphic warning labels.

  • The Indian healthcare sector

    INDIA, 2012/12/15 Recently, much has been said about the healthcare industry in India and its growth. And rightly so; the industry has been gathering steam and making people take notice of its massive growth. Last year, Dr. Prathap C. Reddy, Apollo Hospitals group founder-chairman said in Bangalore that the overall industry will show speedy signs of growth mainly because of increase in life expectancy, higher income levels, greater reach of health insurance, and growing lifestyle-related diseases.

  • The outlook of Pharmaceuticals in China and India

    INDIA, 2011/02/10 With about 52 % of participants coming from India and 40 %  coming from China. European firms were the next most well represented next their Asian counterparts. According to industry experts, the pharmaceutical sector in China and India has been growing at a pace of roughly 15 % to 20 % year-on-year over the completed several years, which is slightly additional than 1.5 times as fast as the increase of each country’s GDP.

  • GCC’s pharmaceuticals industry has bright future(15/12/2010)

    ASIA, 2010/12/15 The GCC’s pharmaceuticals industry will grow at 7% rate in the next decade, according to a new statement from Alpen Capital Projects. In its GCC Pharmaceuticals Industry Statement, it estimate that industry sales would be worth $10.8bn in 2020, up from $5.6bn in 2010. It said the rise would be fueled by factors including long life expectancy, sharp jumps in people increase, increasing healthcare awareness coupled with a rise in lifestyle diseases, conducive government policies and mandatory medical insurance for employees.
Trending Articles